TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14574175

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 37
Study: 9786311

Group type: EXPERIMENTAL
Intervention: 5-FU and leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fluoropyrimidine-based therapies
Number of subjects: 0
Study: 8723583

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg daily) for 14 or 9 days perioperatively, commencing 10 and 5 days preoperatively, respectively.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 2182401

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (50 mg tid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 95488

Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: No chemotherapy (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy with early response
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: No response to BACFON polychemotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy with radiotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy without radiotherapy
Number of subjects: 51
Study: 31086540

Group type: EXPERIMENTAL
Intervention: NIPPV in addition to medicines and oxygen therapy (Intervention Group-A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Multidisciplinary comprehensive respiratory rehabilitation in addition to NIPPV and medicines and oxygen therapy (Intervention Group-B)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (medicines and oxygen therapy)
Number of subjects: 88
Study: 28320800

Group type: EXPERIMENTAL
Intervention: Achieved target sample size
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Achieved more than 80% of target sample size
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Median recruitment rate
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Median retention rate
Number of subjects: 151
Study: 25171902

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/d
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 23265346

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg/day
Number of subjects: 532

Group type: COMPARATOR
Intervention: No colchicine
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg/day (on-treatment analysis)
Number of subjects: 532

Group type: COMPARATOR
Intervention: No colchicine (on-treatment analysis)
Number of subjects: 532
Study: 21358204

Group type: EXPERIMENTAL
Intervention: XELOX (oxaliplatin + oral capecitabine)
Number of subjects: 282

Group type: COMPARATOR
Intervention: FOLFOX-6
Number of subjects: 282
Study: 17965035

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 38
Study: 16491766

Group type: EXPERIMENTAL
Intervention: Point-through-point acupuncture
Number of subjects: 224

Group type: COMPARATOR
Intervention: General needling method (Control)
Number of subjects: 224
Study: 14585280

Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PB and demethylating agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential administration of a demethylating agent and HDAC inhibitors
Number of subjects: 0
Study: 10670599

Group type: EXPERIMENTAL
Intervention: Standard nomogram for managing anticoagulation therapy (Group A, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No nomogram for managing anticoagulation therapy (Group B, n = 10)
Number of subjects: 20
Study: 7853577

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 437

Group type: COMPARATOR
Intervention: RIVM-BCG
Number of subjects: 437

Group type: COMPARATOR
Intervention: Tice BCG
Number of subjects: 437
Study: 2200995

Group type: EXPERIMENTAL
Intervention: Cefuroxime-axetil (250 mg bid)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (500 mg/125 mg bid)
Number of subjects: 157
Study: 6268131

Group type: EXPERIMENTAL
Intervention: MK 421
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lysine analogue
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK 421 or its lysine analogue
Number of subjects: 12
Study: 31150573

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (gemcitabine 1 g/m² on days 1 and 8, cisplatin 80 mg/m² on day 1, every 3 weeks for three cycles) plus concurrent chemoradiotherapy
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (gemcitabine and cisplatin) plus concurrent chemoradiotherapy
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard-therapy (chemoradiotherapy alone)
Number of subjects: 480
Study: 27117700

Group type: EXPERIMENTAL
Intervention: 1×10^6 tolDC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3×10^6 tolDC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10×10^6 tolDC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline irrigation (Control)
Number of subjects: 10
Study: 26513512

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cognitive therapy and Exposure therapy
Number of subjects: 75
Study: 23426348

Group type: EXPERIMENTAL
Intervention: T-tube
Number of subjects: 187

Group type: COMPARATOR
Intervention: No T-tube
Number of subjects: 187
Study: 21193439

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 5715
Study: 19852121

Group type: EXPERIMENTAL
Intervention: 32 U BoNTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 64 U BoNTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 96 U BoNTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (32 U, 64 U, 96 U)
Number of subjects: 60
Study: 17990450

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (Kangliu Zengxiao Decoction during chemotherapy and Feiyanning Decoction after chemotherapy)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine
Number of subjects: 116
Study: 14993134

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with stenting (PCI)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1205
Study: 11396282

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isovolemic CVVH for 5 days starting within 24 h following trauma
Number of subjects: 24
Study: 10093631

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 10
Study: 7919085

Group type: EXPERIMENTAL
Intervention: High body mass index
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 24-hour sodium excretion rates
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 24-hour magnesium/creatinine excretion ratio
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 24-hour sodium excretion rate
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sodium/potassium ratio
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Serum phospholipid
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Serum cholesterol level
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Serum phospholipid n-3 polyunsaturated fatty acid (PUFA) level
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PUFA to saturated fatty acid (SFA) ratio
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 24-hour taurine excretion rate
Number of subjects: 400
Study: 3337653

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine hydrochloride
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no phenoxybenzamine)
Number of subjects: 102
Study: 29705158

Group type: EXPERIMENTAL
Intervention: Functional electrostimulation + standard medical treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calisthenic exercises + standard medical treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 39
Study: 27557918

Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse: CPP-ACP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mousse
Number of subjects: 40
Study: 26715482

Group type: EXPERIMENTAL
Intervention: Psychoeducational tool supported by a telephone call
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study: 24363761

Group type: EXPERIMENTAL
Intervention: Rapamycin plus prednisone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cyclosporine A plus prednisone
Number of subjects: 88
Study: 21406602

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin (induction-positive control)
Number of subjects: 0
Study: 18292443

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscopy (GVL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both GVL and DL
Number of subjects: 20
Study: 17149995

Group type: EXPERIMENTAL
Intervention: Automated telephone outreach
Number of subjects: 6756

Group type: EXPERIMENTAL
Intervention: Live caller outreach
Number of subjects: 6756

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6756
Study: 12960601

Group type: EXPERIMENTAL
Intervention: Dynamic salivary gland scintigraphy in group A (SS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dynamic salivary gland scintigraphy in group B (autoimmune disorders)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dynamic salivary gland scintigraphy in group C (controls)
Number of subjects: 50
Study: 11192143

Group type: EXPERIMENTAL
Intervention: Citalopram oral solution (10 mg/5 mL), 60 mg dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Citalopram tablet, 60 mg dose
Number of subjects: 24
Study: 9490580

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 60
Study: 8238121

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate
Number of subjects: 71
Study: 2418295

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous amrinone (200-400-800 micrograms/kg/h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose intravenous amrinone (800-1600-3200 micrograms/kg/h)
Number of subjects: 16
Study: 31315873

Group type: EXPERIMENTAL
Intervention: A Bite of ACT (online transdiagnostic psychoeducational intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 28321839

Group type: EXPERIMENTAL
Intervention: Identity Project intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 215
Study: 26673432

Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: 595-nm PDL
Number of subjects: 20
Study: 25036539

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gestalt-based intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 102
Study: 22298163

Group type: EXPERIMENTAL
Intervention: Heparin during the procedure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: One venous line cannulation with heparin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Separate cannulation without heparin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall comparison of in situ thrombosis rates by gender
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: One venous line cannulation
Number of subjects: 200
Study: 20557887

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 35
Study: 17367358

Group type: EXPERIMENTAL
Intervention: Risk score derived from Cox regression model
Number of subjects: 399
Study: 15761020

Group type: EXPERIMENTAL
Intervention: G-CSF during chemotherapy (Group B)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy until day 28 or recovery (Group C)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: G-CSF during and after chemotherapy (Group D)
Number of subjects: 722

Group type: COMPARATOR
Intervention: No G-CSF (Group A)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: G-CSF during chemotherapy (Groups B + D)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy (Groups C + D)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy
Number of subjects: 722
Study: 11931679

Group type: EXPERIMENTAL
Intervention: Social phobia group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-anxious group
Number of subjects: 33
Study: 9797551

Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline solution alone (Control)
Number of subjects: 31
Study: 7707405

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (24 Gy in eight fractions over 12 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (control group)
Number of subjects: 300
Study: 2468933

Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg b.i.d.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Quinidine 500 mg b.i.d.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg b.i.d. (after dose adjustment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Quinidine 500 mg b.i.d. (before and after dose adjustment)
Number of subjects: 26
Study: 31751994

Group type: EXPERIMENTAL
Intervention: Breast milk odor (BMO) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incubator cover (IC) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal voice group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29377257

Group type: COMPARATOR
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib 15 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28124822

Group type: EXPERIMENTAL
Intervention: Liraglutide/metformin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo/metformin
Number of subjects: 30
Study: 24226297

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 193) received a pack with tailored information, training plans, behaviour change booklets, and a pedometer.
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (n = 209) received health promotion leaflets.
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Higher doses of the intervention (three or more components).
Number of subjects: 402

Group type: COMPARATOR
Intervention: No use of any aspect of the intervention.
Number of subjects: 402
Study: 23241063

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical periradicular steroid injection (US-CPSI)
Number of subjects: 59
Study: 21397530

Group type: EXPERIMENTAL
Intervention: Invasive treatment (endovascular and/or surgical)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-invasive treatment
Number of subjects: 201
Study: 19035050

Group type: EXPERIMENTAL
Intervention: MSG PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: mtLSU rRNA nested PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: ITS nested PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by MSG PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by mtLSU rRNA nested PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by ITS nested PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sputum samples tested by MSG PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sputum samples tested by mtLSU rRNA nested PCR
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sputum samples tested by ITS nested PCR
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (immunocompetent individuals)
Number of subjects: 145
Study: 16377394

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Standard-dose hemodialysis
Number of subjects: 1846

Group type: COMPARATOR
Intervention: High-dose hemodialysis
Number of subjects: 1846
Study: 12783106

Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy (1 mg/kg twice daily for 14 days, then randomized to 1.0 mg/kg vs. 1.5 mg/kg once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin as a bridge to warfarin (target INR 2.0-3.0)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin as a bridge to warfarin
Number of subjects: 60
Study: 10993961

Group type: EXPERIMENTAL
Intervention: Radiotherapy with mitomycin C (15 mg/M(2) on the first and sixth week of radiotherapy)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Radiotherapy with mitomycin C
Number of subjects: 160

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 160
Study: 8791049

Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2 orally daily for 2 years
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Number of subjects: 437

Group type: COMPARATOR
Intervention: no treatment (observation only)
Number of subjects: 437
Study: 1538722

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg per day given orally)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amphotericin B (1 mg per kilogram of body weight per week given intravenously)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 189
Study: 6548925

Group type: EXPERIMENTAL
Intervention: Almax (hydrated aluminium‐magnesium hydroxycarbonate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Antacid A (aluminium‐magnesium hydroxide codried gel, aluminium hydroxide, calcium carbonate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Almax
Number of subjects: 10

Group type: COMPARATOR
Intervention: Antacid A
Number of subjects: 10
Study: 31502349

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy (MIRH) with no-touch isolation technique
Number of subjects: 109
Study: 30264287

Group type: EXPERIMENTAL
Intervention: 4‐peripheral punches
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 4‐radial cuts
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maltese cross
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (pre‐preparation)
Number of subjects: 9
Study: 26541099

Group type: EXPERIMENTAL
Intervention: Green Dot bystander intervention
Number of subjects: 7111
Study: 24661128

Group type: EXPERIMENTAL
Intervention: GFD-oats
Number of subjects: 71

Group type: COMPARATOR
Intervention: GFD-std
Number of subjects: 71
Study: 22214492

Group type: EXPERIMENTAL
Intervention: Personal digital assistants intervention promoting walking
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perceived access to supportive environments
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perceived environmental barriers
Number of subjects: 14
Study: 19215577

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg qd
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study: 16498265

Group type: EXPERIMENTAL
Intervention: L-NAME (NO synthase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil (cGMP enhancer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (prostaglandin inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine (H1 receptor antagonist)
Number of subjects: 0
Study: 14623703

Group type: EXPERIMENTAL
Intervention: HuMax-CD4 20 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: HuMax-CD4 80 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: HuMax-CD4 160 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: HuMax-CD4 280 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 10922312

Group type: EXPERIMENTAL
Intervention: Low-D(3) group (n = 39)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Active forms of vitamin D supplementation in the low-D(3) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal-D(3) group (n = 12)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 51
Study: 8938009

Group type: EXPERIMENTAL
Intervention: Early-blind group
Number of subjects: 0
Study: 1448266

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3901936

Group type: EXPERIMENTAL
Intervention: 4 mg prostaglandin E2 (PGE2) gel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study: 31442003

Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (11% THC; <1% CBD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: THC/CBD equivalent cannabis (11% THC; 11% CBD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo cannabis (<1% THC; <1% CBD)
Number of subjects: 14
Study: 29271843

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with positive end-expiratory pressure of at least 5 cm H2O
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 219